AKS1-IN-19

CAS No. 2089638-10-6

AKS1-IN-19( AKS1 inhibitor 19 )

Catalog No. M13272 CAS No. 2089638-10-6

A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AKS1-IN-19
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3.
  • Description
    A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3; displays good kinase selectivity with only 32 kinases having less than 30 fold selectivity in a panel of 356 kinases; inhibits phospho-JNK with pEC50 of 8.2 in cellular assays; displayed robust MAP3K pathway inhibition and reduction of infarct size in an isolated perfused heart model of cardiac injury.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AKS1 inhibitor 19
  • Pathway
    MAPK/ERK Signaling
  • Target
    MEK
  • Recptor
    MEK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2089638-10-6
  • Formula Weight
    393.447
  • Molecular Formula
    C21H23N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(C)OC1=CC2=C(CN(C2=O)C3=CC=CC(=N3)C4=NN=CN4C(C)CO)C=C1
  • Chemical Name
    (R)-2-(6-(4-(1-hydroxypropan-2-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-isopropoxyisoindolin-1-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lanier M, et al. ACS Med Chem Lett. 2017 Feb 8;8(3):316-320.
molnova catalog
related products
  • Refametinib R enanti...

    The R enantiomer of Refametinib, a potent, non–ATP-competitive, highly selective, allosteric inhibitor.

  • Vacquinol-1

    Vacquinol-1 (NSC 13316) is a MKK4 (MAP2K4, MEK4) activator that induces vacuolization, induces ATP depletion in glioblastoma cells (IC50 = 3.14 uM) without affecting fibroblasts.

  • MKK7-COV-13

    MKK7-COV-13 (MKK7 Covalen inhibitor 13) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 10 nM.